ASCO
Refine Search
Biotechnology
Shares of Replimune closed up nearly 28% at $7.11 on Thursday after the company shared data on its oncolytic virus RP1 (vusolimogene oderparepvec), in combination with Bristol Myers Squibb’s Opdivo (nivolumab), 7 June 2024
Biotechnology
Gilead subsidiary Kite Pharma has announced updated four-year survival data from the ZUMA-3 study of Tecartus (brexucabtagene autoleucel). 5 June 2024
Biotechnology
Treos Bio, a biotech using data science and proprietary biomarkers to develop precision peptide immunotherapies, has presented results from its Phase II OBERTO-301 study. 4 June 2024
Biotechnology
US drugmaker AbbVie is keen not to be left behind in oncology’s antibody-drug conjugate (ADC) race. 4 June 2024
Biotechnology
French pharma major Sanofi released positive new data from the IMROZ Phase III study at the American Society of Clinical Oncology (ASCO) annual meeting. 4 June 2024
Biotechnology
Japanese pharma giant Takeda and Pfizer have announced positive results from the Phase III HD21 trial at the annual meeting of the American Society of Clinical Oncology (ASCO). 3 June 2024
Biotechnology
Faced with plenty of competition from other drugmakers at the 2024 American Society of Clinical Oncology (ASCO) meeting, Novartis has sought to show the strength of its cancer medicines with its latest data. 3 June 2024
Pharmaceutical
USA-based tumor drug resistance specialist Deciphera Pharmaceuticals today announced results from the company’s MOTION pivotal Phase III study of vimseltinib in patients with Tenosynovial Giant Cell Tumor TGCT) in an oral presentation at ASCO. 3 June 2024
Biotechnology
Positive results have been presented from the LAURA Phase III trial on AstraZeneca’s Tagrisso (osimertinib) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. 3 June 2024
Pharmaceutical
Eli Lilly has released updated data from its Phase I/II clinical trial evaluating olomorasib. 3 June 2024
Pharmaceutical
At the 2024 annual meeting of the American Society of Clinical Oncology (ASCO), Bristol Myers Squibb has announced promising results from the Phase III KRYSTAL-12 study. 3 June 2024
Biotechnology
US biotechs Gilead Sciences and Arcus Biosciences on Saturday announced longer-term efficacy and safety results from Arm A1 of the Phase II EDGE-Gastric study. 3 June 2024
Interview
With a steady flow of oncology results emerging from the ongoing ASCO meeting, a company such as Pierre Fabre, which does not have major data to present, might not usually claim the spotlight. 3 June 2024
Biotechnology
Researchers from UK-based biotech Immunocore Holdings shared new data at the American Society of Clinical Oncology (ASCO) meeting on Kimmtrak (tebentafusp-tebn), the first-ever treatment approved for metastatic uveal melanoma (mUM), showing there is treatment benefit for patients with stable disease and any confirmed tumor reduction. 3 June 2024
Pharmaceutical
US cancer-focussed firm Karyopharm Therapeutics presented updated exploratory subgroup analyses from the Phase III SIENDO study in patients with advanced or recurrent TP53 wild-type endometrial cancer at the American Society of Clinical Oncology (ASCO). 2 June 2024
Biotechnology
US healthcare giant Johnson & Johnson (NYSE: JNJ) released new data from the Phase III MARIPOSA study demonstrating the efficacy of first-line treatment with Rybrevant (amivantamab) in combination with lazertinib in non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. 1 June 2024
ASCO 2024
]S pharma giant Pfizer was trading more than 1% higher during Friday morning’s New York activity. 31 May 2024
Biotechnology
With the annual meeting of the American Society of Clinical Oncology (ASCO) now just days away, multiple large drugmakers have lifted the lid on data that they intend to present. 29 May 2024
Biotechnology
The annual meeting of the American Society of Clinical Oncology (ASCO) is set to commence on 2 June in Chicago, with the highly anticipated plenary session taking place on the Sunday. 22 May 2024
Pharmaceutical
Swiss cancer giant Novartis and German drugmaker Bayer are among the latest companies to lift the lid on upcoming data presentations at ASCO 2024. 17 May 2024
Biotechnology
Data from a pilot study of cancer candidate CTL119, in combination with ibrutinib, will soon be made available by Basel-based Novartis. 31 May 2017
Pharmaceutical
Germany’s Merck KGaA has not appeared near the summit of any rankings on top pharma companies by oncology revenue in recent years, with earnings from its sole cancer product Erbitux (cetuximab) dropping to below $1 billion in 2016. 31 May 2017
Biotechnology
Speaking with The Pharma Letter ahead of the upcoming annual meeting of the American Society of Clinical Oncology, Michael Pehl says that: “We are really excited about the event - we have a really broad range of clinical data.” 26 May 2017
Biotechnology
Colorectal cancer (CRC) exemplifies the steady progress we’ve made in cancer prevention and treatment, writes Dr Samuel Klempner, director of precision medicine at The Angeles Clinic & Research Institute, in the first oncology-themed Expert View piece being published around this year's ASCO Annual Meeting. 25 May 2017
Pharmaceutical
In the run up to the annual meeting of the American Society of Clinical Oncology, we present the first of three analyses focusing on the state of cancer research and care. This week, our correspondent Simon Wentworth reviews progress in the much-anticipated field of precision oncology. 23 May 2017
Pharmaceutical
As the industry’s major players begin to release their curtain raisers, presentation schedules and abstracts ahead of ASCO’s annual meeting, it’s possible to gain some insight into the likely key themes at this year’s event. 19 May 2017
Biotechnology
California-headquartered biotech major Amgen will provide a public update on several key Phase III programs at next month’s annual meeting of the American Society of Clinical Oncology. 19 May 2017
Pharmaceutical
German drugmaker Merck KGaA and US pharma giant Pfizer have promised that 13 abstracts on avelumab across seven hard-to-treat cancers will be presented at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting. 19 May 2017
Pharmaceutical
No fewer than 20 medicines from Swiss pharma giant Roche will be included in more than 190 abstracts being presented at next month’s 2017 American Society of Clinical Oncology (ASCO) Annual Meeting. 12 May 2017
Pharmaceutical
The Pharma Letter's Katie Osborne sums up some of the most exciting research and innovative new cancer treatments presented at this year's annual meeting of the American Society of Clinical Oncology. 12 June 2016
Biotechnology
Recent data from the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting have shown that rovalpituzumab tesirine (Rova-T), AbbVie’s (NYSE: ABBV) antibody-drug conjugate (ADC) to treat recurrent/refractory small cell lung cancer (SCLC), represents a promising new approach, as it is the first biomarker-directed therapy for treating the disease, an aggressive form of lung cancer that accounts for around 15% of all lung cancers. 11 June 2016
Biotechnology
Merck & Co has published updated findings from its Keynote-012 trials for its head and neck cancer drug Keytruda (pembrolizumab) at the American Society of Clinical Oncologists (ASCO) 2016 conference. 10 June 2016
Pharmaceutical
A pilot study has shown the huge differences in retail prices of cancer drugs in different countries, and highlighted the burden the cost puts on patients in many parts of the world. 7 June 2016
Biotechnology
US pharma major AbbVie has announced longer-term follow-up results from Phase III studies of Imbruvica (ibrutinib) in chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL). 7 June 2016
Pharmaceutical
The vice president of the United States Joe Biden has called for greater collaboration across the oncology treatment community in the fight against cancer. 7 June 2016
Biotechnology
Germany’s Merck (MRK: DE) and US pharma giant Pfizer (NYSE: PFE) plan to file for accelerated approval of avelumab for the treatment of patients with metastatic merkel cell carcinoma (MCC), it has been revealed. 6 June 2016
Pharmaceutical
CHICAGO: Anglo-Swedish drugmaker AstraZeneca has released 'encouraging' early research data for Tagrisso (osimertinib) in patients with leptomeningeal (LM) disease at the American Society of Clinical Oncology (ASCO) annual meeting. 6 June 2016
Biotechnology
US pharma major Bristol-Myers Squibb has presented new data on Opdivo (nivolumab) in fighting renal cell carcinoma and on its use with Yervoy (ipilimumab) in advanced melanoma at the 2016 American Society of Clinical Oncology (ASCO) Meeting. 6 June 2016
Biotechnology
Swiss pharma giant Roche has presented Phase II data showing that Tecentriq (atezolizumab) shrank tumours in people with previously untreated advanced bladder cancer. 6 June 2016
Biotechnology
BioNTech, a privately-held German biotech, has been credited with finding the first example worldwide of a clinically relevant and systemic mRNA cancer immunotherapy. 6 June 2016
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze